Search Results - "Turnquist, David J."

Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity by Cornelius, Peter, Mayes, Benjamin A, Petersen, John S, Turnquist, David J, Dufour, Pierre J, Dannenberg, Andrew J, Shanahan, James M, Carver, Bradley J

“…Methionine aminopeptidase type 2 (METAP2) is a ubiquitous, evolutionarily conserved metalloprotease fundamental to protein biosynthesis which catalyzes removal…”
Get more information

Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities by Vohidov, Farrukh, Andersen, Jannik N, Economides, Kyriakos D, Shipitsin, Michail V, Burenkova, Olga, Ackley, James C, Vangamudi, Bhavatarini, Nguyen, Hung V.-T, Gallagher, Nolan M, Shieh, Peyton, Golder, Matthew R, Liu, Jenny, Dahlberg, William K, Ehrlich, Deborah J. C, Kim, Julie, Kristufek, Samantha L, Huh, Sung Jin, Neenan, Allison M, Baddour, Joelle, Paramasivan, Sattanathan, de Stanchina, Elisa, KC, Gaurab, Turnquist, David J, Saucier-Sawyer, Jennifer K, Kopesky, Paul W, Brady, Samantha W, Jessel, Michael J, Reiter, Lawrence A, Chickering, Donald E, Johnson, Jeremiah A, Blume-Jensen, Peter

“…Prodrugs engineered for preferential activation in diseased versus normal tissues offer immense potential to improve the therapeutic indexes (TIs) of…”
Get full text

Abstract CT153: SDX-7320 elicits improvements in tumor-related and metabolic biomarkers: Results of a phase 1 dose-escalation study in patients with advanced refractory or late-stage solid tumors by Mita, Monica M., Bendell, Johanna, Mita, Alain C., Gordon, Michael, Sachdev, Jasgit, Carver, Bradley J., Shanahan, James, Mayes, Benjamin, Awerkamp, Kris, Browning, David, Salomon, Neal, Sullivan, Kimberly, Anderson-Villaluz, Alfred, Johnson, Joe, Petersen, John S., Turnquist, David J., Cornelius, Peter

“…Background and Rationale: Metabo-oncology is the study of specific tumor types whose growth and/or metastasis is accelerated by metabolic dysfunction, often…”
Get full text

Abstract LB-062: Development of macromolecular prodrugs of BET-bromodomain inhibitors with superior anti-tumor efficacy that are T-cell sparing and devoid of systemic toxicity by Vohidov, Farrukh, Andersen, Jannik N., Economides, Kyriakos D., Shipitsin, Michail V., Burenkova, Olga, Gallagher, Nolan M., Sheih, Peyton, Golder, Matthew, Liu, Jenny, Dahlberg, William K., Nguyen, Hung V., Ehrlich, Deborah J., Kim, Julie, Huh, Sung Jin, Vangamudi, Bhavatarini, Neenan, Allison M., Ackley, James C., Baddour, Joelle, Paramasivan, Sattanathan, KC, Gaurab, Turnquist, David J., Saucier-Sawyer, Jenny K., Kopesky, Paul W., Brady, Samantha W., Jessel, Michael J., Reiter, Lawrence A., Chickering, Donald E., Johnson, Jeremiah A., Blume-Jensen, Peter

“…Small molecule BET inhibitors are promising anti-cancer agents, but their clinical development has been limited by hematological and gastrointestinal (GI)…”
Get full text